4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) CEO Duncan Peyton tells Proactive the group has received the green light for a first-in-human trial of its Parkinson’s disease candidates in the US. This is after the FDA approved investigational new drug applications for MRx0005 and MRx0029.
4D said expects to get its phase I study underway in the middle of the year Both prospective treatments are what the company describes as live biotherapeutic products (LBP), meaning they are derived from the human microbiome, the bacterial ecosystem that resides mainly in the gut.